Steichen O
Sorbonne université, Inserm, institut Pierre-Louis d'épidémiologie et de santé publique, équipe Sentinelles, 75012 Paris, France; Assistance publique-Hôpitaux de Paris (AP-HP), Sorbonne université, CHU de Tenon, service de médecine interne, 4, rue de la Chine, 75020 Paris, France.
Rev Med Interne. 2023 Apr;44(4):158-163. doi: 10.1016/j.revmed.2023.01.008. Epub 2023 Jan 27.
Hypertension is the modifiable risk factor causing the largest loss in healthy life-years. The risk of cardiovascular events increases exponentially with the level of blood pressure (BP), starting from 115mmHg for systolic BP. Out-of-office BP measurements (self-measurements or ambulatory BP measurements) are now preferred for the diagnosis and follow up. In the absence of a preferred indication, antihypertensive treatment is based on thiazide diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. These treatments are associated with a significant reduction in morbidity and mortality in people with office BP ≥ 140/90mmHg (self-measurements ≥ 135/85mmHg). For people at high cardiovascular risk, especially those with a history of cardiovascular disease, starting the treatment for an office BP ≥ 130/80mmHg is also beneficial (self-measurements ≥ 130/80mmHg as well). It is now common to start treatment with half-dose dual therapy, which is more effective and better tolerated than full-dose monotherapy. The clinical effect is assessed at 4 weeks and intensification, if required, is then usually done by switching to the same dual therapy at full-dose for both components.
高血压是导致健康生命年损失最大的可改变风险因素。心血管事件的风险随着血压(BP)水平呈指数级增加,收缩压从115mmHg起。目前,非诊室血压测量(自我测量或动态血压测量)更适合用于诊断和随访。在没有优先指征的情况下,降压治疗基于噻嗪类利尿剂、钙通道阻滞剂、血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂。这些治疗可使诊室血压≥140/90mmHg(自我测量≥135/85mmHg)的人群的发病率和死亡率显著降低。对于心血管风险高的人群,尤其是有心血管疾病史的人群,诊室血压≥130/80mmHg(自我测量也≥130/80mmHg)时开始治疗也有益处。现在通常开始采用半量联合治疗,其比全量单药治疗更有效且耐受性更好。在4周时评估临床效果,如有必要强化治疗,通常通过将两种成分都转换为全量的相同联合治疗来进行。